ORGS · As filed with the SEC
Orgenesis cash flow statement, by fiscal year
The statement as Orgenesis presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Profit or Loss | (49,013) | (64,918) | (12,169) | (18,059) |
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||||
| Stock-Based Compensation Expense | 3,194 | 463 | 982 | 1,745 |
| Capital gain, net | — | — | (170) | 25 |
| Share in loss (income) of associated company | — | — | — | 272 |
| Convertible loans induced conversion expenses | 4,304 | — | — | — |
| Capital gain, net | (1,580) | — | — | — |
| Loss (gain) from deconsolidation of OBI, Korea and Belgium subsidiaries in 2024 (Octomera in 2023) | (4,480) | 5,343 | — | — |
| Share in loss of associated companies, net | 8 | 734 | 1,508 | — |
| Depreciation Expense | 2,086 | 1,560 | 1,978 | 1,864 |
| Credit loss on convertible loan receivable | — | 2,688 | — | — |
| Impairment of investment | — | 699 | — | — |
| Credit loss net related to OBI, Korea and Belgium subsidiaries | 2,049 | — | — | — |
| Amortization of Intangibles | 18,338 | — | 1,061 | — |
| Effect of exchange differences on inter-company balances | 2,447 | 227 | 502 | 341 |
| Net changes in operating leases | 1,588 | (50) | (61) | (4) |
| Interest Expense | — | — | 1,372 | 482 |
| Change in Contingent consideration | (4,643) | — | — | — |
| Interest expense accrued on loans and convertible loans | 1,538 | 1,508 | — | — |
| Loss from extinguishment in connection with convertible loan restructuring | 5,422 | 283 | 52 | 1,865 |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 130 | 30,060 | (21,051) | (12,178) |
| Prepaid expenses, other accounts receivable | 2,262 | 432 | 391 | (173) |
| Inventory | 34 | (389) | (7) | 55 |
| Decrease (increase) in other assets | — | — | 26 | (18) |
| Other assets | 43 | 13 | — | — |
| Related parties, net | (2) | (439) | — | — |
| Accounts payable | (1,279) | 5,516 | (1,321) | (3,755) |
| Change in Accrued Liabilities | (820) | 1,013 | 1,570 | (248) |
| Change in Accrued Liabilities | 1,300 | 411 | (216) | 487 |
| Change in Deferred Revenue | — | — | 10 | — |
| Change in advance payments and receivables on account of grant, net | — | — | 722 | 433 |
| Deferred taxes, net | (2) | 9 | (103) | — |
| Net cash used in operating activities | (17,076) | (14,837) | (24,924) | (26,866) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Repayment of convertible loan to related party partners | — | — | 538 | — |
| Decrease in loan to associate entities | — | 55 | — | — |
| Increase in loan to associate entities | — | — | (4,131) | — |
| Loan granted | — | — | — | (818) |
| Net Cash from Financing Activities | — | — | 782 | — |
| Investment in convertible loan to related party | — | — | — | (3,000) |
| Loan to associate | — | — | — | (430) |
| Proceeds from Sale of PP&E | — | — | 246 | — |
| Purchase of property, plants and equipment | (263) | (2,096) | (12,416) | (7,866) |
| Investment in associated company | — | (660) | — | (242) |
| Investment in deposits | — | — | — | (28) |
| Net Cash from Investing Activities | 139 | — | 702 | — |
| Impact to cash resulting from deconsolidation of OBI, Korea and Belgium subsidiaries (see note 20) | (11) | (973) | — | — |
| Increase in cash from business combinations of TLABS and Orgenesis Austria | — | — | 160 | — |
| Investment in long-term deposits | — | (33) | (14) | — |
| Investment in long-term deposits | 500 | — | — | — |
| Net cash used in investing activities | 365 | (3,707) | (14,133) | (12,384) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Repurchase of treasury stock | — | — | — | (1,016) |
| Proceeds from issuance of shares due to exercise of options and warrants (net of transaction costs) | 2,556 | 5,283 | 2,181 | 1,926 |
| Proceeds from Debt Issuance | 75 | 5,735 | 19,150 | — |
| Proceeds from Stock Issuance | — | 5,000 | 20,000 | — |
| Repayment of convertible loans and convertible bonds | — | (3,000) | (2,300) | (1,000) |
| Repayment of short and long-term debt | (226) | (35) | (46) | (16) |
| Proceeds from issuance of loans payable | 6,060 | 635 | — | — |
| Proceeds from Debt Issuance | 774 | — | 1,396 | — |
| Transfer of the grant received to third party | — | — | (803) | — |
| Receipt from Germfree (see note 13f) | 6,720 | — | — | — |
| Net cash provided by financing activities | 15,959 | 13,618 | 39,578 | (106) |
| NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (752) | (4,926) | 521 | (39,356) |
| Effect of Exchange Rate on Cash | (40) | 36 | (126) | (238) |
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR | 1,479 | 6,369 | 5,974 | 45,568 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR | 687 | 1,479 | 6,369 | 5,974 |
| SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES | ||||
| Purchase of property, plant and equipment included in accounts payable | — | — | — | 331 |
| Recognition of finance lease liability and right-of-use assets | — | — | 136 | — |
| Recognition of operating lease liability and right-of-use assets | — | — | 432 | — |
| Net Cash from Operating Activities | 16,007 | — | — | — |
| Net Cash from Operating Activities | 405 | 752 | — | — |
| Increase (decrease) in accounts payable related to purchase of property, plant and equipment | — | 14 | (383) | — |
| Loan conversion for Redeemable non-controlling interest (See note 3) | — | — | 10,203 | — |
| Issuance of common stocks in connection with the acquisition of Mida | — | — | 100 | — |
| Extinguishment in connection with convertible loan restructuring | — | — | — | 1,848 |
| Extinguishment in connection with convertible loan restructuring | 5,281 | 287 | 226 | — |
| CASH PAID DURING THE YEAR FOR: | ||||
| Interest Expense | 4 | 785 | 458 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.